Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Outlook Therapeutics, Inc. Common Stock

OTLK

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Last trade $0.36
Day change -$0.036 (-9.09%)
Day range $0.353 – $0.415
Volume 3,978,750
Market cap $96M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$97.38M
Price / earnings
—
Price / book
-9.37×
Price / sales
-90.86×
EV / sales
-97.38×
EV / EBITDA
-2.73×

Profitability

Earnings per share
-$0.20
Return on assets
-182.66%
Return on equity
460.24%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-1.75×
Current ratio
0.81×
Quick ratio
0.63×
Cash ratio
0.39×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$56.15M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for OTLK, quarterly periods
Line itemQ3 FY2026 Jun 30, 2026Q2 FY2026 Mar 31, 2026Q1 FY2026 Dec 31, 2025Q4 FY2025 Sep 30, 2025Q3 FY2025 Jun 30, 2025Q2 FY2025 Mar 31, 2025Q1 FY2025 Dec 31, 2024Q4 FY2024 Sep 30, 2024
Revenue$8.7K$127.44K-$1.21M—$1.51M$0$0$0
Cost of revenue$16.97K$149.33K$29.63K$0$439.82K$0$0$0
Gross profit-$8.27K-$21.89K-$1.24M—$1.07M$0$0$0
Selling, general and administrative$7.55M$9.5M$8.61M—$9.68M$7.98M$11.95M$10.35M
Research and development$3.25M$4.5M$3.63M—$7.13M$4.41M$9.66M$12.52M
Total operating expenses$10.8M$14.01M$12.25M—$16.81M$12.39M$21.61M$22.88M
Operating income-$10.81M-$14.03M-$13.48M—-$15.75M-$12.39M-$21.61M-$22.88M
Interest expense$7$0$0—-$49.35K$0$48.88K-$666.2K
Income before taxes-$20.32M-$4.45M-$23.06M—-$20.15M-$46.35M$17.38M$5.69M
Income taxes$0$0$0—$0$2.8K$0$0
Net income-$20.32M-$4.45M-$23.06M—-$20.15M-$46.36M$17.38M$5.69M
Net income attributable to common shareholders-$20.32M-$4.45M-$23.06M—-$20.15M-$46.36M$17.38M$5.69M
EBITDA-$10.8M-$14M-$13.45M$29.74K-$15.72M-$12.36M-$21.58M-$22.85M
Basic earnings per share-$0.15-$0.05-$0.38—-$0.55-$1.50$0.72$0.24
Diluted earnings per share-$0.15-$0.05-$0.38—-$0.55-$1.50$0.72$0.27

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

LYTENAVA Sales Forecast and Market Size Analysis 2020-2034: FDA Setback Shapes LYTENAVA Commercial Path

Outlook Therapeutics' LYTENAVA (bevacizumab gamma) received a Complete Response Letter from the FDA in December 2025, preventing approval for wet AMD treatment in the US. The drug is approved in Europe and positioned as a mid-priced alternative between compounded bevacizumab and premium anti-VEGF therapies, with potential expansion into branch retinal vein occlusion and diabetic macular edema indications.

GlobeNewswire Inc.

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Outlook Therapeutics announced FDA approval of LYTENAVA™ (bevacizumab-vikg), the first FDA-approved ophthalmic formulation of bevacizumab specifically designed for treating wet AMD. The approval provides 12 years of market exclusivity under BPCIA and positions the company to capture market share in the approximately $8.5 billion U.S. retina market. The company is launching commercial operations and expects to make LYTENAVA™ available to patients before year-end.

GlobeNewswire Inc.

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Outlook Therapeutics announced a $5.0 million registered direct offering of 8.5 million shares at $0.5855 per share to its largest stockholder GMS Ventures and Investments. The company also agreed to amend outstanding warrants held by GMS Ventures, reducing the exercise price from $1.78 to $0.5855 per share. Proceeds will be used for working capital and general corporate purposes.

Benzinga

Outlook Therapeutics Announces Proposed Public Offering

Outlook Therapeutics (NASDAQ: OTLK) announced a best-efforts public offering of common stock and accompanying warrants to raise capital for working capital and general corporate purposes. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is subject to market conditions with no assurance of completion timing or terms.

Benzinga

Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus

U.S. stock futures rose on the first trading day of 2026, with the S&P 500 and Nasdaq 100 gaining in premarket trading. Key movers included Baidu jumping 12.2% on a spinoff announcement, Rubico surging 16.8% following an acquisition deal, while Outlook Therapeutics plummeted 56.5% after an FDA rejection and Intelligent Bio Solutions dropped 23.4% on a private placement announcement. Analysts predict modest 3-5% gains for 2026 after a record-breaking 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 14, 20241-for-20reverse split
Mar 18, 20191-for-8reverse split